Pharmacokinetics, interactions and mechanism of action of maraviroc;Maraviroc: Farmacocinética, interacciones y mecanismo de acción

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 26, Issue SUPPL. 11, 2008, Pages 12-16

  Soriano, Vicente ^a   Poveda, Eva ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

CCR5 antagonists; Drug interactions; HIV; Maraviroc; Pharmacokinetics

Indexed keywords

ANTIRETROVIRUS AGENT; BERLOCOMBIN; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CYTOCHROME P450 3A4; EFAVIRENZ; ETRAVIRINE; FLUCONAZOLE; FOSAMPRENAVIR; ITRACONAZOLE; KETOCONAZOLE; LEVONORGESTREL; MARAVIROC; MIDAZOLAM; PEGINTERFERON; RIBAVIRIN; RIFAMPICIN; SAQUINAVIR; TIPRANAVIR; BETA CHEMOKINE; CHEMOKINE RECEPTOR CCR5; CYCLOHEXANE DERIVATIVE; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; TRIAZOLE DERIVATIVE; VIRUS ENVELOPE PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; DRUG EXCRETION; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY CLEARANCE; KIDNEY FAILURE; NONHUMAN; RECOMMENDED DRUG DOSE; VIRUS REPLICATION; ADOLESCENT; ADULT; AGED; BIOAVAILABILITY; BIOTRANSFORMATION; CHEMISTRY; DRUG ANTAGONISM; DRUG DESIGN; DRUG EFFECT; DRUG INTERACTION; KIDNEY DISEASE; LIVER DISEASE; MEMBRANE FUSION; METABOLISM; PHYSIOLOGY; REVIEW; STATISTICS; VIRUS ATTACHMENT; VIRUS ENTRY;

ADOLESCENT; ADULT; AGED; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; CHEMOKINES, CC; CLINICAL TRIALS AS TOPIC; CYCLOHEXANES; CYTOCHROME P-450 CYP3A; DRUG DESIGN; DRUG INTERACTIONS; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; KIDNEY DISEASES; LIVER DISEASES; MEMBRANE FUSION; RECEPTORS, CCR5; TRIAZOLES; VIRUS ATTACHMENT; VIRUS INTERNALIZATION; VIRUS REPLICATION;

EID: 65449132341     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/S0213-005X(08)76558-3     Document Type: Article

References (19)

1. Ficha técnica de Maraviroc. Agencia Europea del medicamento. Publicada 15-10-2007. Disponible en: www.emea.europa.eu
2. S. Abel, E. Van der Ryst, M. Rosario, C. Ridgway, C. Medhurst, R. Taylor-Worth, et al. Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers Br J Clin Pharmacol 65 2008 5 18
3. J. Dumond, K. Patterson, A. Pecha, R. Werner, E. Andrews, B. Damle, et al. Maraviroc pharmacokinetics in blood plasma, genital tract fluid and tissue in healthy female volunteers 15th Conference on Retroviruses and Opportunistic Infections Boston 2007 [abstract 135LB]
4. S. Abel, D. Russell, A. Whitlock, G. Ridgway, A. Nedderman, and D. Walker Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects Br J Clin Pharmacol 65 2008 60 67
5. S. Abel, T. Jenkins, L. Whitlock, C. Ridgway, and G. Muirhead Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers Br J Clin Pharmacol 65 2008 38 46
6. S. Abel, D. Russell, L. Whitlock, C. Ridgway, and G. Muirhead The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in healthy volunteers Br J Clin Pharmacol 65 2008 47 53
7. S. Abel, D. Russell, L. Whitlock, C. Ridgway, and G. Muirhead Effect of maraviroc on the pharmacokinetics of midazolam, lamivudine/zidovudine, and ethinyloestradiol/levonorgestrel in healthy volunteers Br J Clin Pharmacol 65 2008 19 26
8. A. Pozniak, M. Boffito, D. Russell, C. Ridgway, and G. Muirhead A novel drug interaction study to investigate the effect of selected antiretroviral combinations on the pharmacokinetics of a singe oral dose of maraviroc in HIV-positive subjects Br J Clin Pharmacol 65 2008 54 59
9. P. Dorr, M. Westby, S. Dobbs, P. Griffin, B. Irvine, and M. Mcartney Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-HIV type 1 activity Antimicrob Agents Chemother 49 2005 4721 4732 (Pubitemid 41552605)
10. E. Comier, and T. Dragic The crown and stem of the V3 loop play distinct roles in HIV type 1 envelope glycoprotein interactions with the CCR5 coreceptor J Virol 76 2002 8953 8957 (Pubitemid 34864089)
11. S. Chan, R. Speck, C. Power, S. Gaffen, B. Chesebro, and M. Godsmithe V3 recombinants indicate a central role for CCR5 as coreceptor in tissue infection by HIV type 1 J Virol 73 1999 2350 2358
12. M. Jensen, and A. Van't Wout Predicting HIV-1 coreceptor usage with sequence analysis AIDS Rev 19 2003 145 149
13. L. Castonguay, Y. Wengg, W. Adolfsen, J. Di Salvo, R. Kilburn, and C. Caldwell Binding of 2-aryl-4(piperidin-1yl)butanmines and 1, 3, 4-trisubstitued pyrrolidines to human CCR5: a molecular modelling-guide mutagenesis study of the binding pocket Biochemistry 42 2003 1544 1550 (Pubitemid 36205961)
14. F. Cocchi, A. DeVico, A. Garzino-Demo, A. Cara, R. Gallo, and P. Lusso Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+T cells Science 270 1995 1811 1815 (Pubitemid 3011045)
15. R. Liu, W. Paxton, S. Choe, D. Unutmaz, M. Burkhart, and P. Di Marzio Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection Cell 86 1996 367 377 (Pubitemid 26272077)
16. M. Dean, M. Carrington, C. Winkler, G. Huttley, M. Smith, R. Allikments, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, San Francisco City Cohort, ALIVE Study Science 273 1996 1856 1862
17. M. Baba, O. Nishimura, N. Kanzaki, M. Okamoto, H. Sawada, and Y. Lizawa A small-molecule, non-peptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity Proc Natl Acad Sci U S A 96 1999 5698 5703 (Pubitemid 29234681)
18. FDA approves maraviroc tablets. AIDS Patient Care & STDs. 2007; 21:702.
19. D. Hardy, J. Reynes, I. Konourina, R. Wheeler, S. Moreno, E. Van der Ryst, et al. Efficacy and safety of Maraviroc plus optimized background therapy in treatment-experienced patients infected with CCR5-tropic HIV-1: 48-week combined analysis of the MOTIVATE studies 15th Conference on Retroviruses and Opportunistic Infections Boston 2008 [abstract 792]